Prognostic significance of atrial arrhythmias in a primary prevention ICD population

PACE - Pacing and Clinical Electrophysiology

Volumn 34, Issue 9, 2011, Pages 1070-1079

  Van Gelder, Isabelle C ^a,b   Phan, Huy M ^e   Wilkoff, Bruce L ^c   Brown, Mark L ^d   Rogers, Tyson ^d   Peterson, Brett J ^d   Birgersdotter Green, Ulrika M ^e  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^c LERNER RESEARCH INSTITUTE   (United States)

^d MEDTRONIC INC   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

appropriate shocks; atrial fibrillation; defibrillators; implantable; primary prevention

Indexed keywords

AGED; ARTICLE; DEFIBRILLATOR; ELECTRIC SHOCK; FEMALE; FOLLOW UP; HEART ATRIUM ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIMARY PREVENTION; PROGNOSIS; RISK ASSESSMENT; SUPRAVENTRICULAR TACHYCARDIA;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HEART FAILURE; HEART RATE; HUMANS; MALE; PREVALENCE; PRIMARY PREVENTION; PROGNOSIS; RETROSPECTIVE STUDIES; TACHYCARDIA, SUPRAVENTRICULAR; TREATMENT OUTCOME;

EID: 80052526212     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2011.03124.x     Document Type: Article

References (41)

1. Young JB, Abraham WT, Smith AL, Leon AR, Liebermann R, Wilkoff B, Canby RC, et al., for the Multicenter Insync ICD Randomized Clinical Evaluation (MIRACLE ICD) Trial Investigators. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: The MIRACLE ICD trial. JAMA 2003; 289: 2685-2694. (Pubitemid 37430139)
2. Wilkoff BL, Ousdigian KT, Sterns LD, Wang ZJ, Wilson RD, Morgan JM, EMPIRIC Trial Investigators. A comparison of EMpiric to Physician-tailored programming of Implantable Cardioverter-defibrillators: Results from the prospective randomized multicenter EMPIRIC trial. J Am Coll Cardiol 2006; 48: 330-339.
3. Neuberger HR, Mewis C, van Veldhuisen DJ, Schotten U, van Gelder IC, Allessie MA, Böhm M,. Management of atrial fibrillation in patients with heart failure. Eur Heart J 2007; 28: 2568-2577. (Pubitemid 350071511)
4. Middlekauff HR, Stevenson WG, Stevenson LW,. Prognostic significance of atrial fibrillation in advanced heart failure. Circulation 1991; 84: 40-48.
5. Stevenson WG, Stevenson LW, Middlekauff HR, Fonarow GC, Hamilton MA, Woo MA, Saxon LA, et al,. Improving survival for patients with atrial fibrillation and advanced heart failure. J Am Coll Cardiol 1996; 28: 1458-1463. (Pubitemid 26391850)
6. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW,. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: A retrospective analysis of the SOLVD trials. J Am Coll Cardiol 1998; 32: 695-703. (Pubitemid 28435256)
7. Wyse DG, Love JC, Yao Q, Carlson MD, Cassidy P, Greene LH, Martins JB, et al,. Atrial fibrillation: A risk factor for increased mortality-an AVID registry analysis. J Interv Card Electrophysiol 2001; 5: 267-273. (Pubitemid 32843441)
8. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, D'Agostino RB, et al,. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham Heart Study. Circulation 2003; 107: 2920-2925. (Pubitemid 36736633)
9. Carson PE, Johnson GR, Dunkman WB, Fletcher RD, Farrell L, Cohn JN,. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group. Circulation 1993; 87 (Suppl 6): VI102-VI110. (Pubitemid 23164229)
10. Mahoney P, Kimmel S, DeNofrio D, Wahl P, Loh E,. Prognostic significance of atrial fibrillation in patients at a tertiary medical center referred for heart transplantation because of severe heart failure. Am J Cardiol 1999; 83: 1544-1547. (Pubitemid 29250037)
11. Crijns HJ, Tjeerdsma G, de Kam PJ, Boomsma F, van Gelder IC, Van Den Berg MP, van Veldhuisen DJ,. Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. Eur Heart J 2000; 21: 1238-1245. (Pubitemid 30487771)
12. Stevenson WG, Stevenson LW,. Atrial fibrillation and heart failure-five more years. N Engl J Med 2004; 351: 2437-2440. (Pubitemid 40485996)
13. Gronefeld GC, Mauss O, Li YG, Klingenheben T, Hohnloser SH,. Association between atrial fibrillation and appropriate implantable cardioverter defibrillator therapy: Results from a prospective study. J Cardiovasc Electrophysiol 2000; 11: 1208-1214.
14. Stein KM, Euler DE, Mehra R, Seidl K, Slotwiner DJ, Mittal S, Markowitz SM, et al,. Do atrial tachyarrhythmias beget ventricular tachyarrhythmias in defibrillator recipients? J Am Coll Cardiol 2002; 40: 335-340. (Pubitemid 34756297)
15. Smit MD, Van Dessel PF, Rienstra M, Nieuwland W, Wiesfeld AC, Tan ES, Anthonio RL, et al,. Atrial fibrillation predicts appropriate shocks in primary prevention implantable cardioverter-defibrillator patients. Europace 2006; 8: 566-572. (Pubitemid 44295749)
16. Rienstra M, Smit MD, Nieuwland W, Tan ES, Wiesfeld AC, Anthonio RL, Van Den Berg MP, et al,. Persistent atrial fibrillation is associated with appropriate shocks and heart failure in patients with left ventricular dysfunction treated with an implantable cardioverter defibrillator. Am Heart J 2007; 153: 120-126. (Pubitemid 44880874)
17. Singh JP, Hall WJ, McNitt S, Wang H, Daubert JP, Zareba W, Ruskin JN, et al,. Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: Findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II). J Am Coll Cardiol 2005; 46: 1712-1720. (Pubitemid 41531628)
18. Zareba W, Steinberg JS, McNitt S, Daubert JP, Piotrowicz K, Moss AJ,. Implantable cardioverter-defibrillator therapy and risk of congestive heart failure or death in MADIT II patients with atrial fibrillation. Heart Rhythm 2006; 3: 631-637.
19. Whang W, Mittleman MA, Rich DQ, Wang PJ, Ruskin JN, Tofler GH, Muller JE, et al,. TOVA Investigators. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: Results from the Triggers of Ventricular Arrhythmias (TOVA) study. Circulation 2004; 109: 1386-1391. (Pubitemid 38387825)
20. Singh SN, Poole J, Anderson J, Hellkamp AS, Karasik P, Mark DB, Lee KL, et al,. SCD-HeFT Investigators. Role of amiodarone or implantable cardioverter/defibrillator in patients with atrial fibrillation and heart failure. Am Heart J 2006; 152: 974.e7-e11.
21. Van Den Berg MP, van Gelder IC, van Veldhuisen DJ,. Impact of atrial fibrillation on mortality in patients with chronic heart failure. Eur J Heart Fail 2002; 4: 571-575. (Pubitemid 35278507)
22. Borleffs CJ, van Rees JB, van Welsenes GH, Van Der Velde ET, van Erven L, Bax JJ, Schalij MJ,. Prognostic importance of atrial fibrillation in implantable cardioverter-defibrillator patients. J Am Coll Cardiol 2010; 55: 879-885.
23. Wilkoff BL, Stern R, Williamson B, Wathen M, Holloman K, Fieberg A, Brown M,. Design of the Primary Prevention Parameters Evaluation (PREPARE) trial of implantable cardioverter defibrillators to reduce patient morbidity. Trials 2006; 7: 18.
24. Wilkoff BL, Williamson B, Stern R, Moore S, Lu F, Lee S, Birgersdotter-Green, UM, et al,., for the PREPARE Study Investigators: Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients. Results from the PREPARE (Primary Prevention Parameters Evaluation) Study. J Am Coll Cardiol 2008; 52: 541-550.
25. Van Gelder IC, van Veldhuisen DJ, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, Bosker HA, et al,. Rate control efficacy in permanent atrial fibrillation: A comparison between lenient versus strict rate control in patients with and without heart failure. Background, aims, and design of RACE II. Am Heart J 2006; 152: 420-426. (Pubitemid 44233429)
26. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, Hillege HL, et al,., the RACE II Investigators. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010; 362: 1363-1373.
27. Ousdigian K, Johnson B, Koehler J, Wilkoff B., Continuous ICD diagnostics triage patients for urgent intervention: Low vs. high risk of inappropriate shocks for AF. Heart Rhythm 2008; 5: S82.
28. Grimm W, Hoffmann JJ, Muller HH, Maisch B,. Implantable defibrillator event rates in patients with idiopathic dilated cardiomyopathy, nonsustained ventricular tachycardia on Holter and a left ventricular ejection fraction below 30%. J Am Coll Cardiol 2002; 39: 780-787 (Pubitemid 34185323)
29. Venkataraman G, Strickberger SA,. Atrial fibrillation degenerates into ventricular fibrillation. J Am Coll Cardiol 2010; 55: 1050.
30. Lerman BB,. Mechanoelectrical feedback: Maturation of a concept. J Cardiovasc Electrophysiol 1996; 7: 17-19.
31. Stein KM, Karagounis LA, Markowitz SM, Anderson JL, Lerman BB,. Heart rate changes preceding ventricular ectopy in patients with ventricular tachycardia caused by reentry, triggered activity, and automaticity. Am Heart J 1998; 136: 425-434. (Pubitemid 28413539)
32. Denker S, Lehmann M, Mahmud R, Gilbert C, Akhtar M,. Facilitation of ventricular tachycardia induction with abrupt changes in ventricular cycle length. Am J Cardiol 1984; 53: 508-515. (Pubitemid 14188821)
33. Grimm W, Flores BF, Marchlinski FE,. Electrocardiographically documented unnecessary, spontaneous shocks in 241 patients with implantable cardioverter defibrillators. Pacing Clin Electrophysiol 1992; 15 (11 Pt 1): 1667-1673.
34. Schmitt C, Montero M, Melichercik J,. Significance of supraventricular tachyarrhythmias in patients with implanted pacing cardioverter defibrillators. Pacing Clin Electrophysiol 1994; 17: 295-302. (Pubitemid 24092111)
35. Bunch TJ, Day JD, Olshansky B, Stolen KQ, Mullin CM., the INTRINSIC RV Investigators. Newly detected atrial-fibrillation in patients with an implantable cardioverter-defibrillator is a strong risk marker of increased mortality. Heart Rhythm 2009; 6: 2-8.
36. Hoppe UC, Casares JM, Eiskjaer H, Hagemann A, Cleland JG, Freemantle N, Erdmann E,. Effect of cardiac resynchronization on the incidence of atrial fibrillation in patients with severe heart failure. Circulation 2006; 114: 18-25. (Pubitemid 44305270)
37. Gasparini M, Auricchio A, Metra M, Regoli F, Fantoni C, Lamp B, Curnis A, et al,., for the Multicentre Longitudinal Observational Study (MILOS) group. Long-term survival in patients undergoing cardiac resynchronization therapy: The importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation. Eur Heart J 2008; 29: 1644-1652. (Pubitemid 351957539)
38. Glotzer TV, Hellkamp AS, Zimmerman J, Sweeney MO, Yee R, Marinchak R, Cook J, et al,. MOST Investigators. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke report of the atrial diagnostics ancillary study of the Mode Selection Trial (MOST). Circulation 2003; 107: 1614-1619. (Pubitemid 36397330)
39. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL,. Stroke with intermittent atrial fibrillation: Incidence and predictors during aspirin therapy. J Am Coll Cardiol 2000; 35: 183-187. (Pubitemid 30061278)
40. Connolly SJ, Kerr CR, Gent M, Roberts RS, Yusuf S, Gillis AM, Sami MH, et al,. Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. N Engl J Med 2000; 342: 1385-1391. (Pubitemid 30262395)
41. Lamas GA, Lee KL, Sweeney MO, Ven Silverman R, Leon A, Yee R, Marinchak RA, et al,. Ventricular pacing or dual chamber pacing for sinus-node. N Engl J Med 2002; 346: 1854-1862. (Pubitemid 34603029)